AI Article Synopsis

  • A patient diagnosed with sarcomatoid renal cell carcinoma had a tumor thrombus in the inferior vena cava.
  • The treatment involved nivolumab and ipilimumab, leading to tumor shrinkage.
  • This enabled a successful robot-assisted laparoscopic radical nephrectomy, and the patient remains cancer-free with no recurrence.*

Article Abstract

We here present a patient with a sarcomatoid renal cell carcinoma complicated by inferior vena cava tumor thrombus that we treated with nivolumab plus ipilimumab. This resulted in shrinkage of the tumor, enabling complete resection by robot-assisted laparoscopic radical nephrectomy. The patient is still alive with no evidence of recurrence.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10764663PMC
http://dx.doi.org/10.1007/s13691-023-00627-5DOI Listing

Publication Analysis

Top Keywords

sarcomatoid renal
8
renal cell
8
cell carcinoma
8
inferior vena
8
vena cava
8
cava tumor
8
tumor thrombus
8
robot-assisted laparoscopic
8
laparoscopic radical
8
radical nephrectomy
8

Similar Publications

Background And Objective: Our aim was to determine the clinical characteristics, temporal trends, and survival outcomes for sarcomatoid-dedifferentiated renal cell carcinoma (sRCC), as sRCC has historically had poor prognosis and a contemporary cohort has not been well characterized in a population-based study.

Methods: Data for 302 630 RCC cases from 2010 to 2019 were extracted from the National Cancer Data Base, of which 4.1% (12 329) were sRCC.

View Article and Find Full Text PDF

Unclassifiable Renal Cell Carcinoma With an Estimated 100% Sarcomatoid Component: A Case Report.

Cureus

December 2024

Department of Anatomopathology, Mohammed VI University Hospital/Faculty of Medicine, Mohammed 1st University, Oujda, MAR.

Sarcomatoid renal cell carcinoma (RCC) is an aggressive tumour with a poor prognosis. It is not a distinct histological entity, as it can be found in any subtype of renal cell carcinoma. The majority of cases will present with advanced or metastatic disease requiring systemic treatment.

View Article and Find Full Text PDF

Bladder cancer is one of the main causes of urogenital cancer (30-35% of the total urological cancers). Although metastases from urologic tumors are rare, it is associated with a high mortality rate. The location and pattern of metastasis are random and unpredictable.

View Article and Find Full Text PDF

Case 332: Tyrosine Kinase Inhibitor-induced Intestinal Lymphangiectasia.

Radiology

December 2024

From the Department of Radiology, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ 85054.

History A 65-year-old male patient with a history of sarcomatoid renal cell carcinoma and prior right nephrectomy developed recurrent disease adjacent to the inferior vena cava. The patient underwent surveillance imaging 7 months after initiation of treatment with maximum-dose pazopanib and less than 1 month after completing a 2-month regimen of palliative stereotactic body radiation therapy to the right nephrectomy bed and site of recurrence. (Stereotactic body radiation therapy was initiated 5 months after pazopanib treatment was initiated.

View Article and Find Full Text PDF

Introduction: Renal cell carcinoma (RCC) involves serosal surfaces in 2%-3% of cases, and thus few papers describe serous fluid cytology (SFC) involvement by RCC. This diagnosis is challenging, given its rarity, nondescript cytomorphologic features and infrequent expression of widely used epithelial markers MOC31 and BerEP4. We describe our institutional experience with RCC in SFC specimens.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!